Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells

Infection and Immunity

Volumn 73, Issue 7, 2005, Pages 4054-4061

  Akiyoshi, D E ^a   Rich, C M ^a   O'Sullivan Murphy, S ^a   Richard, L ^a   Dilo, J ^a   Donohue Rolfe, A ^a   Sheoran, A S ^a   Chapman Bonofiglio, S ^a   Tzipori, S ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; MONOCLONAL ANTIBODY 5C12; UNCLASSIFIED DRUG; VEROTOXIN 2;

ANIMAL CELL; ANTIBIOTIC THERAPY; ARTICLE; BINDING AFFINITY; CHO CELL; CONTROLLED STUDY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HEMOLYTIC UREMIC SYNDROME; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; CERCOPITHECUS AETHIOPS; CHO CELLS; CRICETINAE; FEMALE; HUMANS; MICE; MOLECULAR SEQUENCE DATA; SHIGA-LIKE TOXIN II; VERO CELLS;

EID: 21544447530     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.73.7.4054-4061.2005     Document Type: Article

References (61)

1. Alt, F. W., R. E. Kellems, J. R. Bertino, and R. T. Schimke. 1978. Selective amplification of dihydrofolate reductase genes in methotrexate- resistant variants of cultured murine cells. J. Biol. Chem. 252:1357-1370.
2. Andersen, D. C., and L. Krummen. 2002. Recombinant protein expression for therapeutic applications. Curr. Opin. Biotechnol. 13:117-123.
3. Armstrong, G. D., P. C. Rowe, P. Goodyer, E. Orrbine, T. P. Klassen, G. Wells, A. MacKenzie, H. Lior, C. Blanchard, F. Auclair, et al. 1995. A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J. Infect. Dis. 171:1042-1045.
4. Arunachalam, B., S. Ghosh, G. P. Talwar, and R. Raghupathy. 1992. A single human monoclonal antibody that confers total protection from tetanus. Hybridoma 11:165-179.
5. Banatvala, N. P., P. M. Griffin, K. D. Greene, T. J. Barrett, W. F. Bibb, J. H. Green, and J. G. Wells. 2001. The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J. Infect. Dis. 183:1063-1070.
6. Barnes, L. M., C. M. Bentley, and A. J. Dickson. 2003. Stability of protein production from recombinant mammalian cells. Biotechnol. Bioeng. 81:632-639.
7. Berth, N., M. Zeyda, and H. Katinger. 2001. Efficient selection of high-producing subclones during gene amplification of recombinant Chinese hamster ovary cells by flow cytometry and cell sorting. Biotechnol. Bioeng. 71: 266-273.
8. Chadd, H. E., and S. M. Chamow. 2001. Therapeutic antibody expression technology. Curr. Opin. Biotechnol. 12:188-194.
9. Chin, J., S. Yeowon, S. H. Lee, Y. I. Park, and M. J. Choi. 2003. Production of a neutralizing human monoclonal antibody directed to tetanus toxin in CHO cell. Biologicals 31:45-53.
10. Chu, L., and D. K. Robinson. 2001. Industrial choices for protein production by large-scale cell culture. Curr. Opin. Biotechnol. 12:180-187.
11. Dohi, H., Y. Nishida, Y. Furuta, S. Uzawa, S. Yokoyama, S. Ito, H. Mori, and K. Kobayashi. 2002. Molecular design and biological potential of galacto-type trehalose as a nonnatural ligand of Shiga toxins. Org. Lett. 4:355-357.
12. Dohi, H., Y. Nishida, M. Mizuno, M. Shinkai, T. Kobayashi, T. Takeda, H. Uzawa, and K. Kobayashi. 1999. Synthesis of an artificial glycoconjugate polymer carrying Pk-antigenic trisaccharide and its potent neutralization activity against Shiga-like toxin. Bioorg. Med. Chem. 7:2053-2062.
13. Donohue-Rolfe, A., D. W. Acheson, A. V. Kane, and G. T. Keusch. 1989. Purification of Shiga toxin and Shiga-like toxins I and II by receptor analog affinity chromatography with immobilized P1 glycoprotein and production of cross-reactive monoclonal antibodies. Infect. Immun. 57:3888-3893.
14. Donohue-Rolfe, A., I. Kondova, J. Mukherjee, K. Chios, D. Hutto, and S. Tzipori. 1999. Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2. Infect. Immun. 67:3645-3648.
15. Edwards, A. C., A. R. Melton-Celsa, K. Arbuthnott, S. J. R., C. K. Schmitt, H. C. Wong, and A. O'Brien. 1998. Vero cell neutralization and mouse protective efficacy of humanized monoclonal antibodies against Escherichia coli toxins Stx1 and Stx2, p. 388-392. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology, Washington, D.C.
16. Fishwild, D. M., S. L. O'Donnell, T. Bengoechea, D. V. Hudson, F. Harding, S. L. Bernhard, D. Jones, R. M. Kay, K. M. Higgins, S. R. Schramm, and N. Lonberg. 1996. High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol. 14:845-851.
17. Goochee, C. F., M. J. Gramer, D. C. Andersen, J. B. Bahr, and J. R. Rasmussen. 1991. The oligosaccharides of glycoproteins: bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties. Biotechnology 9:1347-1355.
18. Islam, M. S., and W. H. Stimson. 1990. Production and characterization of monoclonal antibodies with therapeutic potential against Shiga toxin. J. Clin. Lab. Immunol. 33:11-16.
19. Kaufman, R. J., and P. A. Sharp. 1982. Amplification and expression of sequences cotransfected with a modular dihydrofolate reductase complementary DNA gene. J. Mol. Biol. 159:601-621.
20. Kitov, P. I., J. M. Sadowska, G. Mulvey, G. D. Armstrong, H. Ling, N. S. Pannu, R. J. Read, and D. R. Bundle. 2000. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403:669-672.
21. Kozak, M. 1999. Initiation of translation in prokaryotes and eukaryotes. Gene 234:187-208.
22. Kwaks, T. H., P. Barnett, W. Hemrika, T. Siersma, R. G. Sewalt, D. P. Satijin, J. F. Brons, R. van Blokland, P. Kwakman, A. L. Kruckeberg, A. Kelder, and A. P. Otte. 2003. Identification of anti-repressor elements that confer high and stable protein production in mammalian cells. Nat. Biotechnol. 21:553-558.
23. Lonberg, N., L. D. Taylor, F. A. Harding, M. Trounstine, K. M. Higgins, S. R. Schramm, C.-C. Kuo, R. Mashayekh, K. Wymore, J. G. McCabe, D. Munoz-O'Regan, S. L. O'Donnell, E. S. G. Lapachet, T. Bengoechea, D. M. Fishwild, C. E. Carmack, R. M. Kay, and D. Huszar. 1994. Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368:856-859.
24. Lund, J., N. Takahashi, S. Hindley, R. Tyler, M. Goodall, and R. Jefferis. 1993. Glycosylation of human IgG subclass and mouse IgG2b heavy chains secreted by mouse J558L transfectoma cell lines as chimeric antibodies. Hum. Antibodies Hybridomas 4:20-25.
25. Maynard, J., and G. Georgiou. 2000. Antibody engineering. Annu. Rev. Biomed. Eng. 2:339-376.
26. Mead, S. P., L. Slutsker, V. Dietz, L. F. McCaig, J. S. Bresee, G. Shapiro, P. M. Griffin, and R. V. Tauxe. 1999. Food-related illness and death in the United States. Emerg. Infect. Dis. 5:607-625.
27. Mellon-Celsa, A. R., and A. D. O'Brien. 1998. Structure, biology, and relative toxicity of Shiga toxin family members for cells and animals, p. 121-128. In J. B. Kaper and A. D. O'Brien (ed.), Escherichia coli O157:H7 and other Shiga toxin-producing E. coli strains. American Society for Microbiology Press, Washington, D.C.
28. Mukherjee, J., K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S. M. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect. Immun. 70:612-619.
29. Mukherjee, J., K. Chios, D. Fishwild, D. Hudson, S. O'Donnell, S. M. Rich, A. Donohue-Rolfe, and S. Tzipori. 2002. Production and characterization of protective human antibodies against Shiga toxin 1. Infect. Immun. 70:5896-5899.
30. Nishikawa, K., K. Matsuoka, E. Kita, N. Okabe, M. Mizuguchi, K. Hino, S. Miyazawa, C. Yamasaki, J. Aoki, S. Takashima, Y. Yamakawa, M. Nishijima, D. Terunuma, H. Kuzuhara, and Y. Natori. 2002. A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc. Natl. Acad. Sci. USA 99:7669-7674.
31. O'Brien, A. D., and R. K. Holmes. 1987. Shiga and Shiga-like toxins. Microbiol. Rev. 51:206-220.
32. Padhye, V. V., T. Zhao, and M. P. Doyle. 1989. Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from Escherichia coli of serotype O 157:H7. J. Med. Microbiol. 30:219-226.
33. Page, M. J., and M. A. Sydenham. 1991. High level expression of the humanized monoclonal antibody CAMPATH-1H in Chinese hamster ovary cells. Biotechnology 9:64-68.
34. Paton, A. W., R. Morona, and J. C. Paton. 2000. A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat. Med. 6:265-270.
35. Paton, A. W., R. Morona, and J. C. Paton. 2001. Neutralization of Shiga toxins Stx1, Stx2c, and Stx2e by recombinant bacteria expressing mimics of globotriose and globotetraose. Infect. Immun. 69:1967-1970.
36. Paton, J. C., and A. W. Paton. 1998. Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin. Microbiol. Rev. 11:450-479.
37. Perera, L. P., L. R. Marques, and A. D. O'Brien. 1988. Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J. Clin. Microbiol. 26:2127-2131.
38. Persic, L., A. Roberts, J. Wilton, A. Cattaneo, A. Bradbury, and H. R. Hoogenboom. 1997. An integrated vector system for the eukaryotic expression of antibodies or their fragments after selection from phage display libraries. Gene 187:9-18.
39. Raife, T., and R. Montgomery. 2001. New aspects in the pathogenesis and treatment of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Rev. Clin. Exp. Hematol. 5:236-261.
40. Raju, T. S., J. Briggs, S. M. Borge, and A. J. S. Jones. 2000. Species-specific variation in glycosylation of IgG: evidence for the species-specific sialylation and branch-specific galactosylation and importance for engineering recombinant glycoprotein in therapeutics. Glycobiology 10:477-486.
41. Ray, P. E., and X. H. Liu. 2001. Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr. Nephrol. 16:823-839.
42. Reff, M. E. 1993. High-level production of recombinant immunoglobulins in mammalian cells. Curr. Opin. Biotechnol. 4:573-576.
43. Roque, A. C. A., C. R. Lowe, and M. A. Taipa. 2004. Antibodies and genetically engineered related molecules: production and purification. Biotechnol. Prog. 20:639-654.
44. Sambrook, J., and D. W. Russell. 2001. Molecular cloning: a laboratory manual, vol. 2, 3rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
45. Schmidt, F. R. 24 July 2004, posting date. Recombinant expression systems in the pharmaceutical industry. Appl. Microbiol. Biotechnol. [Online.] http: //www.springerlink.com.
46. Sheoran, A. S., S. Chapman, P. Singh, A. Donohue-Rolfe, and S. Tzipori. 2003. Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect. Immun. 71: 3125-3130.
47. Simmons, L. C., D. Reilly, L. Klimowski, T. S. Raju, G. Meng, P. Sims, K. Hong, R. L. Shields, L. A. Damico, P. Rancatore, and D. G. Yansura. 2002. Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies. J. Immunol. Methods 263: 133-147.
48. Simonsen, C. C., and M. McGrogan. 1994. The molecular biology of production cell lines. Biologicals 22:85-94.
49. Slutsker, L., A. A. Ries, K. Maloney, J. G. Wells, K. D. Greene, and P. M. Griffin. 1998. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J. Infect. Dis. 177:962-966.
50. Strockbine, N. A., L. R. Marques, R. K. Holmes, and A. D. O'Brien. 1985. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect. Immun. 50:695-700.
51. Subramani, S., R. Mulligan, and P. Berg. 1981. Expression of the mouse dihydrofolate reductase complementary deoxyribonucleic acid in simian virus 40 vectors. Mol. Cell. Biol. 1:854-864.
52. Tarr, P. I., and M. A. Neill. 2001. Escherichia coli O157:H7. Gastroenterol. Clin. North Am. 30:735-751.
53. Trachtman, H., A. Cnaan, E. Christen, K. Gibbs, S. Zhao, D. W. Acheson, R. Weiss, F. J. Kaskel, A. Spitzer, and G. H. Hirschman. 2003. Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 290:1337-1344.
54. Trill, J. J., A. R. Shatzman, and S. Ganguly. 1995. Production of monoclonal antibodies in COS and CHO cells. Curr. Opin. Biotechnol. 6:553-560.
55. Tzipori, S., A. Sheoran, D. Akiyoshi, A. Donohue-Rolfe, and H. Trachtman. 2004. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin. Microbiol. Rev. 17:926-941.
56. Urlaub, G., and L. A. Chasin. 1980. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc. Natl. Acad. Sci. USA 77:4216-4220.
57. Urlaub, G., P. J. Mitchell, E. Kas, L. A. Chasin, V. L. Funanage, T. T. Myoda, and J. Hamlin. 1986. Effect of gamma rays at the dihydrofolate reductase locus: deletions and inversions. Somat. Cell Molec. Genet. 12:555-566.
58. Watanabe, M., K. Matsuoka, E. Kita, K. Igai, N. Higashi, A. Miyagawa, T. Watanabe, R. Yanoshita, Y. Samejima, D. Terunuma, Y. Natori, and K. Nishikawa. 2004. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J. Infect. Dis. 189: 360-368.
59. Wong, C. R., S. Jelacic, R. L. Habeeb, S. L. Watkins, and P. I. Tarr. 2000. The risk of hemolytic-uremic syndrome after antibiotic therapy of Escherichia coli O157:H7 infections. N. Engl. J. Med. 342:1930-1936.
60. Wood, C. R., A. J. Dorner, G. E. Morris, E. M. Alderman, D. Wilson, R. M. O'Hara, and R. J. Kaufman. 1990. High level synthesis of immunoglobulins in Chinese hamster ovary cells. J. Immunol. 145:3011-3016.
61. Yoshikawa, T., F. Nakanishi, Y. Ogura, D. Oi, T. Omasa, Y. Katakura, M. Kishimoto, and K. Suga. 2001. Flow cytometry: an improved method for the selection of highly productive gene-amplified CHO cells using flow cytometry. Biotechnol. Bioeng. 74:435-442.